Reversal effect of 5-Aza-dc on cisplatin-resistance in human NSCLC cells in vitro

Chinese Journal of Oncology

Volumn 33, Issue 5, 2011, Pages 349-353

  Wu, Fang ^a   Hu, Chun Hong ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

5 Aza 2 deoxycytidine; Carcinoma,non small cell lung; Cell line, A549 DDP; Cisplatin; DNA methylation; Drug resistance, neoplasm; hMLH1

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CISPLATIN; PROTEIN MLH1;

ARTICLE; CYTOTOXICITY; IC 50; IN VITRO STUDY; LUNG NON SMALL CELL CANCER; PROTEIN EXPRESSION; PROTEIN METHYLATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CISPLATIN; DNA METHYLATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG NEOPLASMS; NUCLEAR PROTEINS; PROMOTER REGIONS, GENETIC; RNA, MESSENGER;

EID: 80053431433     PISSN: 02533766     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0253-3766.2011.05.008     Document Type: Article

References (8)

1. Strathdee G, MacKean MJ, Illand M, et al. A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Oncogene, 1999, 18:2335-2341. (Pubitemid 29192710)
2. Arnold CN, Coel A, Boland CR. Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines. Int J Cancer, 2003, 106:66-73. (Pubitemid 36750389)
3. Plumb JA, Strathdee G, Sludden J, et al. Reversal of drug resistance in human tumor xenografts by 2′-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res, 2000, 60:6039-6044.
4. Steele N, Finn P, Brown R, et al. Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo. Br J Cancer, 2009, 100:758-763.
5. van Engeland M, Weijenberg MP, Roemen GM, et al. Effects of dietary folate and alcohol intake on promoter methylation in sporadic colorectal cancer: the Netherlands cohort study on diet and cancer. Cancer Res, 2003, 63: 3133-3137. (Pubitemid 36735864)
6. Watanabe Y, Ueda H, Etoh T, et al. A change in promoter methylation of hMLH1 is a cause of acquired resistance to platinum-based chemotherapy in epithelial ovarian cancer. Anticancer Res, 2007, 27:1449-1452. (Pubitemid 46807221)
7. Perez-Plasencia C, Duenas-Gonzalez A. Can the state of cancer chemotherapy resistance be reverted by epigenetic therapy? Mol Cancer, 2006, 5:27.